BRPI0610089A2 - intensificador de resistÊncia À insulina - Google Patents

intensificador de resistÊncia À insulina

Info

Publication number
BRPI0610089A2
BRPI0610089A2 BRPI0610089-9A BRPI0610089A BRPI0610089A2 BR PI0610089 A2 BRPI0610089 A2 BR PI0610089A2 BR PI0610089 A BRPI0610089 A BR PI0610089A BR PI0610089 A2 BRPI0610089 A2 BR PI0610089A2
Authority
BR
Brazil
Prior art keywords
receptor agonist
glp
insulin resistance
dosage regimen
endogenous
Prior art date
Application number
BRPI0610089-9A
Other languages
English (en)
Inventor
Naomi Wakabayashi
Yuriko Harada
Yutaka Masuda
Original Assignee
Asubio Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asubio Pharma Co Ltd filed Critical Asubio Pharma Co Ltd
Publication of BRPI0610089A2 publication Critical patent/BRPI0610089A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

INTENSIFICADOR DE RESISTÊNCIA À INSULINA. A presente invenção refere-se a um novo regime de dosagem de agonistas de receptor de GLP-1 que causa pouco ou nenhum efeito colateral ou interações de fármacos, e é apropriado para aperfeiçoar a resistência à insulina. Além disso, é fornecido um intensificador de resistência à insulina para uso no regime de dosagem. O regime de dosagem compreende administrar repetidamente, de preferência de uma maneira não invasiva, um agonista de receptor de GLP-1 pelo menos antes de comer, por um período de tempo predeterminado, para criar uma condição similar a que é observada com a secreção temporária pós-prandial do agonista de receptor de GLP-1 endógeno, em vez de administrá-lo continuamente. Isto cria uma variação similar ou ampliada nos níveis de plasma do agonista de receptor de GLP-1, quando comparado com a variação circadiana do agonista de receptor de GLP-1 endógeno em um indivíduo sadio. É fornecida também uma composição farmacêutica para uso em um regime de dosagem contendo agonista de receptor de GLP-1 como um ingrediente ativo
BRPI0610089-9A 2005-05-27 2006-05-26 intensificador de resistÊncia À insulina BRPI0610089A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005155312 2005-05-27
PCT/JP2006/310590 WO2006126688A1 (ja) 2005-05-27 2006-05-26 インスリン抵抗性改善剤

Publications (1)

Publication Number Publication Date
BRPI0610089A2 true BRPI0610089A2 (pt) 2008-12-09

Family

ID=37452110

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610089-9A BRPI0610089A2 (pt) 2005-05-27 2006-05-26 intensificador de resistÊncia À insulina

Country Status (11)

Country Link
US (1) US20090233851A1 (pt)
EP (1) EP1886692A4 (pt)
JP (1) JPWO2006126688A1 (pt)
KR (1) KR20080011675A (pt)
CN (1) CN101184509A (pt)
AU (1) AU2006250347A1 (pt)
BR (1) BRPI0610089A2 (pt)
CA (1) CA2606902A1 (pt)
IL (1) IL187230A0 (pt)
RU (1) RU2007149288A (pt)
WO (1) WO2006126688A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351262A1 (en) * 2016-12-30 2018-07-25 Istanbul Universitesi Rektorlugu Curaglutide for in treatment of prediabetes, diabetes, obesity and metabolic diseases associated thereto

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
NZ508823A (en) * 1998-06-12 2003-10-31 Amylin Pharmaceuticals Inc Glucagon-like peptide-1 improves beta-cell response to glucose in subjects with impaired glucose tolerance or increased risk of a cardiovascular or cerebrovascular event
AU2353701A (en) * 2000-01-11 2001-07-24 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
US20020061838A1 (en) * 2000-05-17 2002-05-23 Barton Holmquist Peptide pharmaceutical formulations
WO2002069994A2 (en) * 2001-03-07 2002-09-12 Novo Nordisk A/S Combined use of derivatives of glp-1 analogs and ppar ligands
IL161446A0 (en) * 2001-11-26 2004-09-27 Daiichi Suntory Pharma Co Ltd Medicinal compositions for nasal absorption
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
KR20050049525A (ko) * 2002-10-11 2005-05-25 가부시키가이샤산와카가쿠켄큐쇼 Ｇｌｐ-1 유도체 및 그의 경점막 흡수형 제제
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands

Also Published As

Publication number Publication date
US20090233851A1 (en) 2009-09-17
RU2007149288A (ru) 2009-07-10
JPWO2006126688A1 (ja) 2008-12-25
CA2606902A1 (en) 2006-11-30
KR20080011675A (ko) 2008-02-05
CN101184509A (zh) 2008-05-21
WO2006126688A1 (ja) 2006-11-30
EP1886692A4 (en) 2009-09-30
EP1886692A1 (en) 2008-02-13
AU2006250347A1 (en) 2006-11-30
IL187230A0 (en) 2008-02-09

Similar Documents

Publication Publication Date Title
Molero et al. Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review
Luckenbaugh et al. Do the dissociative side effects of ketamine mediate its antidepressant effects?
Huss et al. Influence of pain and analgesia on orthopedic and wound-healing models in rats and mice
CY1109578T1 (el) Μηχανισμος εμφανισης δοσολογιας για μια συσκευη χορηγησης φαρμακου
ES2526463T3 (es) Exendina para el tratamiento de la diabetes y la reducción del peso corporal
CO6361944A2 (es) Combinacion de una insulina y un agonista de glp-1
CL2021001609A1 (es) Régimen de dosificación y combinación farmacéutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
BRPI0719009B8 (pt) mecanismo de dosagem e acionamento destinado a dispositivos de liberação de fármacos
AR054064A1 (es) Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas
MX339142B (es) Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
ATE439123T1 (de) Verwendung von emulsionen zur intra- und periocularen injection
DE602005010788D1 (de) Pharmazeutische Zusammensetzungen zur sicheren Verabreichung von bei der Behandlung von Drogenabhängigkeit verwendeten Arzneimitteln
NO20072931L (no) Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva
BRPI0511224A (pt) método para preparar uma composição contendo antagonistas de opióides, produto contendo antagonistas de opióides, composição contendo antagonistas de opióides, formulação de dosagem injetável, kit, método para prevenir ou tratar um efeito colateral associado com um opióide num paciente, e para tratar ou impedir dor num paciente
BRPI0418373A (pt) composição farmacêutica, unidade de dosagem de cci-779 oral, método de fornecimento de cci-779 a um paciente, e, uso de cci-779 micronizado
AR062775A1 (es) Composicion farmaceutica capaz de mejorar la actividad de glp -1 en un ser humano y su uso para preparar un medicamento
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
MX2009011900A (es) Curacion de herida diabetica.
MX390667B (es) Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos.
BR0316057A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
PE20040973A1 (es) Composiciones de anti-histaminicos, descongestivos y drogas anti-inflamatorias no esteroidales
BRPI0519656A2 (pt) terapia de combinaÇço compreendendo telmisartan e hidroclorotiazida
ATE361065T1 (de) Pharmazeutische zusammensetzung zur kontrolle des blutzuckers bei patienten mit typ 2 diabetes
EP2392322A3 (en) Dosing regimes for trans-clomiphene
BR112022004535A2 (pt) Formulações de entrega de fármaco

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]